Office of the Deputy Provost | About the Deputy Provost

Lynn Twarog Singer

 

Research

 

 

Research Areas | Grants Received | Patents | Contracts | Research Teams

 

 

Research Areas

Focusing on prenatal and infant subjects, Lynn Singer is concerned with research in the following areas:

 

Cocaine: Cognitive and Motor Outcomes of Cocaine-Exposed Infants

Begun in 1994, this research is a longitudinal investigation of prenatal cocaine exposure.

Project Newborn~Next Steps – Summary

Project Newborn~Next Steps is a longitudinal study of prenatal cocaine exposure funded by the National Institute on Drug Abuse.  This study investigates the developmental outcomes of prenatal cocaine/polydrug exposure in an urban, low socioeconomic, largely African-American population. 

Maternal psychopathology, parenting, characteristics, postnatal drug use, and other environmental risk, conceptualized to influence prenatal exposure effects on child outcomes, are also investigated. 

The study has been funded in three phases beginning in 1994 and refunded in 1998 and 2002.  A cohort of 415 children have been followed since shortly after infant birth and assessed at 6, 12, and 24 months and at 4, 6, 9, and 10 years.

Significance: Prenatal exposure to cocaine continues to be a significant societal problem especially in poor urban areas of the U.S. As there are few methodologically adequate, published follow-up studies beyond the neonatal and infancy period, outcome from four and six year, as well as emering 9 year data, provides important new information.

Longer term follow-up through the adolescent period is necessary to assess persistence and significance of developmental abnormalities and sub-optimal caregiving environments.

Bronchopulmonary dysplasia (BPD) / Chronic lung disease of prematurity

This research is focused on the expanding population of very low birth weight (VLBW) children with BPD, and the long term outcomes of these children, or the adaptation of their families.

Significance: There is a rapidly expanding population of very low birth weight (VLBW) children with Bronchopulmonary dysplasia (BPD); yet there is scant literature documenting the long-term outcomes of these children, or the adaptation of their families.

This study sample includes 3 groups of 14 year-old subjects with the first consisting of VLBW children with BPD, the second consisting of VLBW children without BPD, and a third control group of children born healthy full-term, all of whom have been followed since birth, and who did not differ at birth on confounding factors of race, socioeconomic status, gender or parental education.

This research aims to increase understanding of the long-term needs of children born prematurely both with and without BPD, as well as the long-term needs of their families. In addition it helps to identify risk factors for physical, psychological and educational difficulties, allowing professionals to create a supportive environment when working with these children and their families and enabling policy-makers to make evidence-based decisions in funding programs for them.

MDMA – ecstasy

This research looks at the effects of fetal exposure to methylendioxymethamphetamine (MDMA) commonly known as "ecstasy" and seeks to answer unresolved questions about its effects on humans.

mdmaMethylendioxymethamphetamine (MDMA, "ecstasy") is the fastest growing drug used among young people in the United States. Despite an increasing body of empirical research, there are still many unresolved questions about its effects on humans.

In particular, preclinical studie suggest that fetal exposure to MDMA may have harmful effects on the developing child, yet there are no human studies to date which have developmentally followed MDMA exposed infants.

This study aims to assess preschool outcomes in MDMA exposed children and non-exposed children and the environment and maternal psychological correlates that may reduce or increase risk in MDMA-exposed children.

logoBuilding on an established partnership between Case Western Reserve University, and community research partners at the University of East London, England, the study will continue to follow-up a cohort of MDMA, polydrug exposed children prospectively enrolled prenatally and seen through two-years of age in the United Kingdom.

Approximately 99 women, (33 MDMA users and 66 non-users) and their children will be seen through 2 years. MDMA and other drug exposures were determined by meternal self-report and frequency assessed at each trimester through clinical interview and hair analysis. Standardized questionnaires and assessment measuring maternal pysychological status, personality, social supports, attention, neuropsychological functioning, and cargiving behaviors will be administered, at follow-up and children will be assessed on standardized and experimental measures of growth, cognitive, motor, language, and behavoral outcomes annually.

Data will be evaluated descriptively, and through a series of longitudinal mixed model, hierarchical mutiple/logistic regression analyses, to describe the functioning of MDMA-exposed children and their mothers, and the relative impact of MDMA and other substance exposures on child outcomes, maternal psychological and neuropsychological functioning, and caregiving interactions. Changes over time and predictive models of infant risk, using HLM or structutal equation models, will be utilized. The proposed research will provide information about the early developmental sequelae of fetal MDMA/poydrug-exposure, maternal psychological status and caregiving behaviors which can guide the design of effective maternal drug treatment and child intervention programs.

 

 back to top

Patents

Co-Inventor, P.C.T. Application/USO1/11964, Infant Formulas Containing Long Chain Polyunsaturated Fatty Acids and Uses thereof.   Abbott Laboratories.

 

 back to top

Contracts

AA and DHA “Supplementation in Low Birthweight Infants”.  Ross-Abbott Laboratories, 1998-1999.

 

 back to top

Grants

"Psychosocial Follow-up of Infants with Tracheostomy," 
PI Lynn Singer, Ph.D., Office of Research Administration, Case Western Reserve University,
6/1/82 - 5/31/83, $1,989.

"Developmental Outcome of Infant Tracheostomy,"
PI Lynn Singer, Ph.D., Rainbow Board of Trustees, Rainbow Babies & Childrens Hospital,
1/1/84 - 12/31/85, $10,000.

"Early Medical Correlates & Psychosocial Outcome in Infant Tracheostomy,"
PI Lynn Singer, Ph.D., American Lung Association of Northern Ohio,
7/1/85 - 6/30/87, $30,000.

"Developmental Sequelae of Severe Chronic Lung Disease in Infancy,"
PI Lynn Singer, Ph.D. National Institutes of Health, Heart, Lung, & Blood Institutes,
RO1 HL-38193-01,  7/1/89 - 6/30/94, Direct costs: $848,593.

"Psychosocial Sequelae of Bronchopulmonary Dysplasia & Very Low Birth Weight," PI, Lynn Singer, Ph.D. Maternal & Child Health & Crippled Children's Services Research Grant Program, 10/1/89 - 9/30/92, Direct costs:  $387,867.

"Perinatal Cocaine Center," 
Robert Kliegman, M.D., & Lynn Singer, Ph.D., Co-PI's, Rainbow Board of Trustees,
1/1/90 - 12/31/91, Direct Costs:  $100,000.

"Perinatal Cocaine Abuse Project," 
Robert Kliegman, M.D., & Lynn Singer, Ph.D., Co-PI's, Nord Foundation,
2/19/90 - 2/18/92, Direct Costs:  $33,000.

"Developmental Follow-Up of Cocaine-Exposed Infants,"
Robert Kliegman, M.D., Lynn Singer, Ph.D., Co-PI's, Gund Foundation,
7/15/90 - 12/15/92, Direct Costs: $45,000.

"Follow-Up of Cocaine-Exposed Infants,"
Robert Kliegman, M.D., Lynn Singer, Ph.D., Co-PI's, Cleveland Foundation,
9/30/90 - 9/29/93, Direct Costs: $90,000.

"Maternal-Child Interactions of Cocaine-Exposed Infants",
Lynn Singer, Ph.D., & Robert Kliegman, M.D., Co-PI's, National Foundation March of Dimes, 3/1/91 - 2/28/93, Direct Costs:  $36,000.

"The Home Visitor Project for Chemically Dependent Women and their Children",
PI Kathleen Farkas, Ph.D., Lynn Singer, Co-Investigator, Office of Substance Abuse Prevention, 10/1/91 - 9/30/94,  Direct Costs:  $660,000.

"The Effects of Maternal Employment on the Development of Low Birthweight Infants",
PI Joanne Youngblut, Ph.D., Lynn Singer, PH.D., Co-Investigator, NIH-NCR,
9/1/92 - 8/30/96, Direct Costs:  $800,000.

"Psychosocial Sequelae of Bronchopulmonary Dysplasia & Very Low Birthweight",
Competing Continuation. 
PI, Lynn Singer, Ph.D., Maternal & Child Health Bureau, MCH  -390592,
1/1/93 - 12/31/96, Direct Costs:  $700,000.

"Psychosocial Services to Cocaine-Exposed Infants and Families",
PI, Lynn Singer, Ph.D., Sihler Foundation, Chagrin Falls, Ohio,
5/1993 - 5/1994, Direct Costs:  $34,000.

"Pediatric Health Supervision to Promote Literacy",
PI, Robert Needlman, M.D., Co-PI Lynn Singer, Ph.D., Maternal & Child Health Bureau,
10/1/93 - 9/30/98, Direct Costs:  $443,141.

"Developmental Follow-Up of Cocaine-Exposed Infants",
PI, Lynn Singer, Ph.D., Gund Foundation,
9/1/93 - 8/31/94, Direct Costs:  $64,000.

"Cocaine-Exposed Infants and Their Mothers",
PI Lynn Singer, Ph.D., NIDA,
1/1/94 - 12/31/98, Direct Costs:  $1,617,792  Indirect Costs: $828,999  Total Costs: $2,446,791.

"Cohort Maintenance of Cocaine Exposed Infants",
PI Lynn Singer, Ph.D., NIDA,
1/1/95 - 12/31/98, Direct Costs:  $100,000.

"Psychological Services for Cocaine-Exposed Infants",
PI Lynn Singer, Ph.D., Sihler Mental Health Foundation,
12/01/94 - 11/30/95, Direct Costs:  $28,000.

"Planning a Service Delivery Model for Drug-Using Women and Their Children",
PI Lynn Singer, Ph.D., Cleveland Foundation,
7/01/95 - 6/30/96, Direct Costs:  $54,000.

"Psychological Services for Drug Exposed Infants",
Cuyahoga County Board of Mental Retardation,
1996-1997, $10,000.

"Community Response Proposal for Collaborative Action Projects",
PI, Lynn Singer, Ph.D.,
1/96-12/31/96, United Way, $7,000.

"Psychological Services for Children of Women in Jail",
Lutheran Ministries Community Re-Entry Program, PI, Lynn Singer, Ph.D.,
1/96-12/96, $10,000.

"Research Supplements for Underrepresented Minorities", NIDA,
PI, Lynn Singer, Ph.D.,
5/1/96-6/30/97, D.C., $125,000.

"Psychosocial Sequelae of BPD and VLBW:  Phase II", Maternal and Child Health Services,
PI, Lynn Singer, Ph.D.,
2/1/97-1/31/01, D.C. $896,368, I.C. $475,075, T.C. $1,371,443.

"Cocaine Exposed Infants:  Cardiac Problems and Outcome", NIDA,
PI, Sudhir Mehta, M.D., Lynn Singer-Co-Investigator,
4/1/97-3/31/00, D.C. $855,984, I.C. $427,992, T.C.$1,283,976.

"Child and Family Functioning After Pediatric Head Trauma", NCNR,
PI, Joanne Youngblut, Lynn Singer, Co-Investigator,
6/1/97-5/31/02, D.C. $1,635,249, T.C. $2,399,604.

"Cocaine-Exposed Infants and Their Mothers - 4 and 6 Year Follow-up.  NIDA,
PI, Lynn Singer, Ph.D.,
7/1/98-12/31/02, D.C. $1,807,658, T.C. $2,731,542.

“Research Supplements for Under-Represented Minorities", NIDA,
PI Lynn Singer, Ph.D.,
7/1/98-6/30/99, D.C. $100,000.

"Executive Functioning in Cocaine-Exposed Children", NIDA,
NRSA to Julia Noland, Ph.D., Sponsor Lynn Singer, Ph.D.,
9/1/98-8/31/00, D.C. $60,000.

"Epidemiology of Sleep-Disordered Breathing in Children", NICHHD,
PI Susan Redline, M.D., Co-Investigator, Lynn Singer, Ph.D.,
7/1/98-6/30/02.

"Sensory-Motor Problems of Cocaine-Exposed Children", NIDA,
PI Robert Arendt, Ph.D., Co-Investigator, Lynn Singer, Ph.D.,
9/1/98-8/31/02.

“Antidepressant Use in Pregnancy”, NIMH,
PI Kathy Wisner, M.D., Co-Investigator Lynn Singer, Ph.D.,
8/1/99-7/31/02.

“Dysmorphologic and Anthropometric Assessment of Cocaine-Exposed Children”, NIDA,
PI Lynn Singer, Ph.D.,
12/01/01-12/31/02, TC = $234,190.

“Antidepressant Use in Pregnancy”, NIMH,
PI Lynn Singer, Ph.D.,
4/1/01-3/31/03, TC = $ 293,933.

“Neuroimaging and Neurophysiological Correlates of Prenatal Cocaine Exposure”, NIDA,
PI Lynn Singer,
7/1/00-12/31/02, $360,401.

“Developmental Outcomes of Prenatal Exposure to MDMA (“Ecstasy”), NIDA,
PI Lynn Singer, Ph.D.,
9/30/01-9/28/06, $3,092,647.

“Cocaine Exposed Infants and Their Mothers”
Research Supplement for Underrepresented Minorities,
Sponsor Lynn Singer,
8/27/01-12/30/02, $54,349.

Research Supplements for Underrepresented Minorities,
Predoctoral Fellowship for Teresa Linares, Sponsor Lynn Singer,
1999-2003, $180,000.

Research Supplements for Underrepresented Minorities,
Predoctoral Fellowship for Teresa Linares, Sponsor Lynn Singer,
2003-2006, $99,658.

Psychosocial Sequelae of BPD and VLBW:  Phase 3", Maternal and Child Health Services,
PI Lynn Singer, Ph.D.,
01/01/03-12/31/06, $2,255,089.

“Advance Institutional Transformation Award,” National Science Foundation,
PI Lynn Singer, Ph.D.,
8/1/03 – 7/31/08, $3,500,000.

“Cocaine Exposed Children at School Age”, NIDA,
PI Lynn Singer, Ph.D.,
09/15/03 – 09/34/08, $4,970,000.

 “Oral Health Problems of BPD and VLBW Adolescents”, MCH,
PI Suchitra Nelson, Co-Investigator Lynn Singer, Ph.D.,
09/01/04 – 05/31/07, 5% time. 

Research Supplements for Underrepresented Minorities, Predoctoral Fellowship for AnnaMaria Aguirre, Sponsor Lynn Singer, 2006-2009, $38,625.

“Longitudinal Analyses of the Psychosocial Sequelae of VLBW and BPD, Phases 1-3”, MCH, PI – Lynn Singer, Ph.D., 02/01/08 – 01/31/09, Direct Costs: $100,000.

"Institutions Developing Excellence in Academic Leadership", NSF, PI Lynn T. Singer, Ph.D., 09/01/09 – 08/31/12, $920,000.

"Role of Personal Social Networks in Post Treatment Functioning", PI Elizabeth Tracy, Ph.D., Co-Investigator Lynn T. Singer, Ph.D., 05/01/09 – 04/30/12, $1,113,539.

"Longitudinal Analyses of the Psychosocial Sequelae of VLBW and BPD, Phases 1-3", MCH, PI – Lynn Singer, Ph.D., 02/01/08 – 01/31/10

"The Effects of Prenatal Cocaine Exposure on Adolescent Development", PI Sonia Minnes, Ph.D., Co-Investigator Lynn T. Singer, Ph.D., 07/01/09 – 06/30/14, $4,800,000.

 back to top

 
 

The Office of the Deputy Provost is located in Adelbert Hall, Room 216

Please call 216.368.1610 to request an appointment with the Deputy Provost.

The Office of the Provost is located in Adelbert Hall, Room 216

Please call 216.368.4346 to request an appointment with the Provost.

The organizational chart details the administrative structure of the Deputy Provost's Office. View the chart (PDF)

 
close button

Contact The Office of the Provost

Provost and Executive Vice President: 216.368.4346
Executive Assistant to the Provost: 216.368.4346
Deputy Provost & Vice President for Academic Affairs: 216.368.1610
Vice Provost for Undergraduate Education: 216.368.4389
Executive Assistant to the Deputy Provost: 216.368.1610
Secretary of the University Faculty: 216.368.4316
Special Assistant for Appointments, Promotion, and Tenure: 216.368.4342
Department Assistant:216.368.4389

Still looking? Refer to the university directory for more contact information.